<DOC>
	<DOCNO>NCT02396342</DOCNO>
	<brief_summary>This study evaluate safe gene therapy treatment AAV5-hFIX adult patient severe moderately severe hemophilia B severe bleeding type .</brief_summary>
	<brief_title>Trial AAV5-hFIX Severe Moderately Severe Hemophilia B</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Hemophilia B</mesh_term>
	<criteria>1 . Male 2 . Age ≥ 18 year 3 . Patients congenital hemophilia B classify one following : Known severe FIX deficiency plasma FIX activity level &lt; 1 % severe bleeding phenotype define one following : Currently prophylactic FIX replacement therapy history bleed Currently ondemand therapy current past history frequent bleeding define four bleeding episode last 12 month chronic hemophilic arthropathy ( pain , joint destruction , loss range motion ) one joint Known moderately severe FIX deficiency plasma FIX activity level ≥ 1 % ≤ 2 % severe bleeding phenotype define one following : Currently prophylactic FIX replacement therapy history bleed Currently ondemand therapy current past history frequent bleeding define four bleeding episode last 12 month chronic hemophilic arthropathy ( pain , joint destruction , loss range motion ) one joint 4 . More 150 previous exposure day treatment FIX protein . 5 . Acceptance use condom sexual intercourse period Investigational Medicinal Product ( IMP ) administration AAV5 clear semen , evidence central laboratory negative analysis result least 3 consecutively collect semen sample ( criterion applicable also subject surgically sterilize ) 6 . Following receipt verbal write information trial , subject provide sign informed consent trial related activity carry . 1 . History FIX inhibitor measure ≥ 0.6 Bethesda Units ( BU ) /mL 2 . FIX inhibitor ≥ 0.6 BU/mL Visit 1 ( measure local laboratory ) 3 . Neutralizing antibody AAV5 Visit 1 ( measure central laboratory ) 4 . Visit 1 laboratory value ( measured central laboratory ) : alanine aminotransferase &gt; 2 time upper normal limit aspartate aminotransferase &gt; 2 time upper normal limit total bilirubin &gt; 2 time upper normal limit alkaline phosphatase &gt; 2 time upper normal limit creatinine &gt; 1.5 time upper normal limit 5 . Positive HIV serological test Visit 1 , control antiviral therapy show cluster differentiation 4+ count ≤ 200 per μL viral load &gt; 200 copy per mL ( measured central laboratory ) 6 . Active infection Hepatitis B C virus reflect Hepatitis B Surface Antigen ( HBsAg ) , Hepatitis B extracellular Antigen ( HBeAg ) , Hepatitis B Virus DeoxyriboNucleic Acid ( HBV DNA ) Hepatitis C Virus RiboNucleic Acid ( HCV RNA ) positivity , respectively , Visit 1 ( measure central laboratory ) . 7 . History Hepatitis B C exposure , currently control antiviral therapy 8 . Any coagulation disorder hemophilia B 9 . Thrombocytopenia , define platelet count 50 × 10E9 / L , Visit 1 ( measure central laboratory ) 10 . Body mass index &lt; 16 ≥ 35 kg/m2 11 . Planned surgery initial 6 month IMP administration trial 12 . Previous arterial venous thrombotic event ( e.g . acute myocardial infarction , cerebrovascular disease venous thrombosis ) 13 . Active severe infection significant concurrent , uncontrolled medical condition include , limited , renal , hepatic , haematological , gastrointestinal , endocrine , pulmonary , neurological , cerebral psychiatric disease , alcoholism , drug dependency psychological disorder evaluate investigator interfere adherence protocol procedure degree tolerance IMP 14 . Known significant medical condition include disseminate intravascular coagulation , fibrinolysis liver fibrosis , opinion investigator , may confound , contraindicate limit interpretation either safety efficacy data 15 . Known history allergic reaction anaphylaxis FIX product 16 . Known uncontrolled allergic condition allergy/hypersensitivity component IMP excipients 17 . Previous gene therapy treatment and/or previous participation gene therapy clinical trial 18 . Receipt experimental agent within 60 day prior Visit 1 19 . Current participation anticipate participation within one year IMP administration trial interventional clinical trial involve drug device .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Hemophilia B , gene therapy</keyword>
</DOC>